Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering-Plough, Incyte Report Positive Mid-Stage Data For CCR5 Antagonists

This article was originally published in The Pink Sheet Daily

Executive Summary

Both Schering’s vicriviroc and Incyte’s INCB9471 CCR5 antagonist candidates to treat HIV beat placebo in Phase II trials.

You may also be interested in...



Schering Moves Vicriviroc Phase III Program Forward In HIV

Company has initiated two Phase III studies of the CCR5 receptor antagonist in treatment-experienced HIV patients.

Schering Moves Vicriviroc Phase III Program Forward In HIV

Company has initiated two Phase III studies of the CCR5 receptor antagonist in treatment-experienced HIV patients.

Pfizer’s Selzentry Wins FDA Approval For HIV

First-in-class CCR5 antagonist will be available by mid-September with a wholesale acquisition cost of $29/day based on twice-a-day dosing, Pfizer tells “The Pink Sheet” DAILY.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066365

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel